載入中
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
前收盤價
US$2.41
+US$0.11 · +4.78%
盤中時間採用ET。市場資料可能有所延遲。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日內區間
目前US$2.41
52週區間
目前US$2.41
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
47
合理估值
情緒
50
多空交錯
風險
41
風險偏高
動能
61
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
日內區間
目前US$2.41
52週區間
目前US$2.41
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 83萬 USD | — | — | — | 5萬 USD |
| 毛利 | −83萬 USD | — | — | — | −5萬 USD |
| 研究與開發 | 4826萬 USD | 4379.5萬 USD | 3211.5萬 USD | 2586.2萬 USD | 2811.9萬 USD |
| 銷售、一般及管理費用 | 1469萬 USD | 1059.1萬 USD | 481.9萬 USD | 390.4萬 USD | 1164.9萬 USD |
| 營業費用 | 6212萬 USD | 5438.6萬 USD | 3693.4萬 USD | 2976.6萬 USD | 3976.8萬 USD |
| 利息收入 | 344.1萬 USD | 201.3萬 USD | 162.3萬 USD | 25.4萬 USD | — |
| 利息支出 | — | 30萬 USD | — | — | — |
| 折舊和攤銷 | 83萬 USD | 66.2萬 USD | 56萬 USD | 38.7萬 USD | 5萬 USD |
| 營業利益 | −6295萬 USD | −5438.6萬 USD | −3693.4萬 USD | −2976.6萬 USD | −3981.8萬 USD |
| 淨利 | −5951.7萬 USD | −5267.3萬 USD | −3531.1萬 USD | −2951.2萬 USD | −3977萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.00
上漲空間 480.91%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年10月7日 | 1:10 | — | — |
已生效 2024年10月7日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI418.93萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM133.75萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF110.98萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO54.77萬0.00%180億 USD0.06%US$112.66+0.50%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED21.43萬0.66%3296.48萬 USD0.44%US$33.8094+2.13%
iShares Micro-Cap ETFIWC19.07萬0.01%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM13萬0.11%1.17億 USD0.73%US$15.9402+0.25%
Vanguard Russell 2000 Value ETFVTWV8.81萬0.01%14億 USD0.06%US$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
